Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration - Stewart,A.; Steiner,J.; Mellows,G.; Laguda,B.; Norris,D.; Bevan,P. (Clin Cancer Res, 2000)